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Abstract: Herein the quantitative synthesis of eight new mono- and dianionic Organic Salts and
Ionic Liquids (OSILs) from alendronic acid (ALN) is reported by following two distinct sustainable
and straightforward methodologies, according to the type of cation. The prepared ALN-OSILs
were characterized by spectroscopic techniques and their solubility in water and biological fluids
was determined. An evaluation of the toxicity towards human healthy cells and also human
breast, lung and bone (osteosarcoma) cell lines was performed. Globally, it was observed that the
monoanionic OSILs showed lower toxicity than the corresponding dianionic structures to all cell
types. The highest cytotoxic effect was observed in OSILs containing a [C2OHMIM] cation, in
particular [C2OHMIM][ALN]. The latter showed an improvement in IC50 values of ca. three orders
of magnitude for the lung and bone cancer cell lines as well as fibroblasts in comparison with ALN.
The development of OSILs with high cytotoxicity effect towards the tested cancer cell types, and
containing an anti-resorbing molecule such as ALN may represent a promising strategy for the
development of new pharmacological tools to be used in those pathological conditions.
Keywords: alendronic acid; Active Pharmaceutical Ingredients; API-OSILs; anticancer drugs;
ionic liquids
1. Introduction
Alendronic acid is an aminobisphosphonate derivative that has shown efficacy in postmenopausal
osteoporosis, malignant hypercalcemia and Paget’s disease [1]. Alendronate localizes preferentially
at active sites of bone resorption, which has been inhibited at doses that have no effect on bone
mineralization [2].
Bisphosphonates bind at the bone mineral surface, where they potently inhibit osteoclast-mediated
bone resorption and subsequently embed in the bone, being released only during subsequent
resorption [3]. In contrast to other antiresorptive agents, bisphosphonates with the greatest binding
affinity to bone (zoledronic acid > alendronate > ibandronate > risedronate) may persist in bone,
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and patients continue to be exposed to the pharmacologic effects of these drugs several years
after discontinuation.
All bisphosphonates rapidly reduce bone resorption, which leads to decreased bone formation
because resorption and formation are coupled. Within three to six months, equilibrium is reached at a
lower rate of bone turnover [4].
It is described that alendronate in rats exhibited 200 to 1000 times more potency than etidronate
and approximately 100 times more in comparison with clodronate or tiludronate [5]. It is recognized
that the presence of amino group side-chain from alendronate chemical structure contributes to greater
potency and specificity [3–5].
The introduction of specific functional groups in the BPs structure can lead to modifications in
their physicochemical, biological, therapeutic and toxicological properties. In recent literature studies,
alendronic acid is reported as an FDA drug already approved for the prevention and treatment of
osteoporosis in men and women, either postmenopausal or glucocorticoid-induced [6]. However, BPs
present low bioavailability when administered orally and frequently require parenteral administration,
which is not the most convenient route in case of continuous treatment.
The combination of Active Pharmaceutical Ingredients (APIs) with biocompatible organic
counter-ions has rendered over the last decade an attractive class of materials entitled API–Organic
Salts and Ionic Liquids (API-OSILs) [7–10]. Ionic Liquids (ILs) are defined as salts with a melting
point below 100 ◦C, which display peculiar properties such as negligible vapor pressure, high
thermal and chemical stability and tunable physicochemical properties according to the cation-anion
combinations. These novel API–OSILs can improve the drug performance in terms of stability,
solubility, permeability, biological activity and delivery [10–22]. Recent achievements showed
that the suitable combination between different families of pharmaceutical drugs such as NSAIDs
(e.g., ibuprofen and naproxen [15,16]), β-lactam (e.g., ampicillin, amoxicillin, penicillin [16–20])
and fluoroquinolone (ciprofloxacin, norfloxacin [16,21]) antibiotics and bone antiresorptive agents
(zoledronic acid [22]) rendered novel pharmaceutical drug formulations based on OSILs. Elimination
of original polymorphism, improvement of permeability and solubility in water and biological fluids
as well as increased therapeutic efficiency was observed for these innovative compounds.
Thus, considering the pharmaceutical importance of bisphosphonate drugs as antiresorptive and
potential antitumoral agents, it is of paramount importance that novel formulations of such drugs,
which render higher bioavailability and lower systemic toxicity than the latter are developed. Hence,
in this paper, we report our latest results on our research line regarding bisphosphonate-based OSILs.
In particular, we describe the synthesis of eight new Ionic Liquids and Organic Salts from alendronic
acid (ALN–OSILs) as mono- and dianion by combination with one or two units of biocompatible cations,
respectively. The desired compounds were prepared in quantitative yields by two distinct sustainable
and straightforward methodologies, according to the type of cation. All prepared ALN–OSILs were
characterized by spectroscopic techniques and their solubility in water and biological fluids was
determined. Finally, evaluation of the toxicity towards human healthy cells and lung, breast and bone
(osteosarcoma) cell lines was performed.
2. Synthesis and Characterization of ALN–OSILs
Figure 1 depicts the structures of ALN and the selected cations, which were combined in 1:1 or 1:2
stoichiometric ratios, thereby deprotonating one or two phosphonate groups, respectively.
The selection of protonated organic superbases (1,1,3,3-tetramethylguanidinium [TMGH]
and 1,5-diazabicyclo(4.3.0)non-5-enium [DBNH]) and quaternary ammonium (cholinium [Ch] and
1-(2-hydroxyethyl)-3-methyl-1H-imidazol-3-ium [C2OHMIM]) cations relied on the known information
about their biocompatibility [15,23]. Despite their low toxicity, the combination of these cations
with other APIs has rendered highly active API–OSILs in the past, in particular antimicrobial and
anti-tumoral [19,20,22].
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Figure 1. Structure of mono- and dianionic alendronate, protonated superbases and organic 
quaternary cations used to prepare the alendronic acid (ALN)–Organic Salts and Ionic Liquids 
(OSILs). 
Scheme 1 resumes the synthetic methodologies employed in the synthesis of the API–OSILs. 
 
Scheme 1. Methodologies (A,B) for the preparation of ALN–OSILs. 
The preparation of compounds 1–4 consisted of the addition of the diluted superbases to a 
dispersion of ALN (pathway A). These particular compounds, termed Superionic Liquids of APIs, 
were prepared according to a previous methodology reported by us for zoledronic acid [22] as well 
as other APIs [16]. While both monoanionic ALN–OSILs were obtained as solids, the two dianionic 
were isolated as pastes. 
On the other hand, a combination of ALN with one and two equivalents of [Ch] and [C2OHMIM] 
cations yielded four more ALN-based OSILs (compounds 5–8) by following another methodology 
already described by our group [15,22]. In this case, quaternary ammonium hydroxide cations are 
previously prepared by the corresponding halide exchange with hydroxide exchange resins (e.g., 
Amberlyst A26-OH) in methanolic solution. The very basic solutions were then neutralized by 
addition to an aqueous solution of bisphosphonate yielding the desired salts in quantitative yields. 
From the four synthesized compounds, two are RTILs while the other two are solids (see below). 
All products were characterized by NMR (1H and 13C) and FTIR spectroscopic techniques, as 
well as elemental analysis. The thermal properties were evaluated by DSC and the solubility in water 
and saline solution was determined for all compounds. 
The NMR spectra of the ALN–OSILs were acquired in D2O taking advantage of their high 
solubility in water (see below). In all cases, the 1H NMR spectra showed that the cation/anion 
Figure 1. Structure of mono- and dianionic alendronate, protonated superbases and organic quaternary
cations used to prepare the alendronic acid (ALN)–Organic Salts and Ionic Liquids (OSILs).
Scheme 1 resumes the synthetic methodologies employed in the synthesis of the API–OSILs.
Pharmaceutics 2020, 12, x FOR PEER REVIEW 3 of 10 
 
 
Figure 1. Structure of mono- and dianionic alendronate, protonated superbases and organic 
quaternary cations used to prepare the alendronic acid (ALN)–Organic Salts and Ionic Liquids 
(OSILs). 
Scheme 1 resumes the synthetic methodologies employed in the synthesis of the API–OSILs. 
 
Scheme 1. Methodologies (A,B) for the preparation of ALN–OSILs. 
The preparation of compounds 1–4 consisted of the addition of the diluted superbases to a 
dispersion of ALN (pathway A). These particular compounds, termed Superionic Liquids of APIs, 
were prepared according to a previous methodology reported by us for zoledronic acid [22] as well 
as other APIs [16]. While both monoanionic ALN–OSILs were obtained as solids, the two dianionic 
were isolated as pastes. 
On the other hand, a combination of ALN with one and two equivalents of [Ch] and [C2OHMIM] 
cations yielded four more ALN-based OSILs (compounds 5–8) by following another methodology 
already described by our group [15,22]. In this case, quaternary ammonium hydroxide cations are 
previously prepared by the corresponding halide exchange with hydroxide exchange resins (e.g., 
Amberlyst A26-OH) in methanolic solution. The very basic solutions were then neutralized by 
addition to an aqueous solution of bisphosphonate yielding the desired salts in quantitative yields. 
From the four synthesized compounds, two are RTILs while the other two are solids (see below). 
All products were characterized by NMR (1H and 13C) and FTIR spectroscopic techniques, as 
well as elemental analysis. The thermal properties were evaluated by DSC and the solubility in water 
and saline solution was determined for all compounds. 
The NMR spectra of the ALN–OSILs were acquired in D2O taking advantage of their high 
solubility in water (see below). In all cases, the 1H NMR spectra showed that the cation/anion 
Scheme 1. Methodologies (A,B) for the preparation of ALN–OSILs.
The preparation of compounds 1–4 consisted of the addition of the diluted superbases to a
dispersion of ALN (pathway A). These particular compounds, termed Superionic Liquids of APIs,
were prepared according to a previous methodology reported by us for zoledronic acid [22] as well as
other APIs [16]. While both monoanionic ALN–OSILs were obtained as solids, the two dianionic were
isolated as pastes.
On the other hand, a combination of ALN with one and two equivalents of [Ch] and [C2OHMIM]
cations yielded four more ALN-based OSILs (compounds 5–8) by following another methodology
already described by our group [15,22]. In this case, quaternary ammonium hydroxide cations are
previously prepared by the corresponding halide exchange with hydroxide exchange resins (e.g.,
Amberlyst A26-OH) in methanolic solution. The very basic solutions were then neutralized by addition
to an aqueous solution of bisphosphonate yielding the desired salts in quantitative yields. From the
four synthesized compounds, two are RTILs while the other two are solids (see below).
All products were characterized by NMR (1H and 13C) and FTIR spectroscopic techniques, as well
as elemental analysis. The thermal properties were evaluated by DSC and the solubility in water and
saline solution was determined for all compounds.
The NMR spectra of the ALN–OSILs were acquired in D2O taking advantage of their high solubility
in water (see below). In all cases, the 1H NMR spectra showed that the cation/anion proportion is
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strictly 1.0:1.0 or 2.0:1.0, in agreement with the intended stoichiometry (see Figures S1–S16). In addition,
only one set of signals was observed, meaning that the reactions were complete and only one product
was formed. No comparison with alendronic acid is achievable because of its lack of solubility in the
same solvents as the ALN–OSILs. In the 13C NMR spectra, the resonance of the quaternary carbon
atom of ALN appears at ca. 74 ppm, with no particular difference if only one or two neighboring
phosphonate groups are deprotonated. Similarly, the 1H NMR data is also irreflective of the ionic state
of the bisphosphonates and also of the cations. In contrast, the collected FTIR spectra (Figures S17–S25)
show pristine variations between the neutral bisphosphonates and the ALN–OSILs, as well as between
mono- and dianions. The FTIR spectrum of ALN shows two characteristic regions, namely a weak and
undefined structure at 2400–2000 cm−1 with maximum intensity at 2256 cm−1, and also very intense
multiple peaks at 1250–900 cm−1 (see Figure 2A). While the first one accounts for O–H stretches from
the O=P–OH groups, the second region contains peaks assignable to the stretch of both P=O and P–OH
bonds [24]. In the spectra of the synthesized ALN–OSILs (see Figure 2 for [TMGH]-based ALN–OSILs),
the peaks in the first region become sharper and much weaker, and two other sets of peaks appear
in the vicinity (at ca. 2400–2300 cm−1 and 2200–2100 cm−1) which are more intense for the dianionic
ALN–OSILs than for the monoanionic. This is in complete agreement with changes in the vibrational
modes of the OH groups from the phosphonate moieties that are particularly enhanced when both
groups are deprotonated. This corollary is also sustained by the changes observed in the second region
of peaks, which in general displays two very intense broad peaks at ca. 1160 cm−1 and 1060 cm−1, and
one or two of medium intensity between 960 and 900 cm−1.
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Thermal Analysis of ALN–OSILs 
All prepared OSILs from alendronic acid were studied by Differential Scanning Calorimetry 
(DSC) techniques (see Figures S26–S33). Table 1 contains the obtained data, namely melting, 
crystallization and glass transition temperatures, as well as the physical state of the analyzed 
compounds. 
In general, the monoanionic ALN–OSILs are foam-like solids while the dianionic ones were 
obtained as thick colorless pastes at room temperature, thus being considered Room Temperature 
Ionic Liquids (RTILs). The exceptions to this rule are the compounds with the [C2OHMIM] cation, 
where the mono- and dianionic are, respectively, a paste and a foam. This inversion of the trend is 
probably related to specific interactions of ALN with the electron-rich imidazolium ring [25]. 
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3. Thermal Analysis of ALN–OSILs
All prepared OSILs from alendronic acid were studied by Differential Scanning Calorimetry (DSC)
techniques (see Figures S26–S33). Table 1 contains the obtained data, namely melting, crystallization
and glass transition temperatures, as well as the physical state of the analyzed compounds.
In general, the monoanionic ALN–OSILs are foam-like solids while the dianionic ones were
obtained as thick colorless pastes at room temperature, thus being considered Room Temperature Ionic
Liquids (RTILs). The exceptions to this rule are the compounds with the [C2OHMIM] cation, where
the mono- and dianionic are, respectively, a paste and a foam. This inversion of the trend is probably
related to specific interactions of ALN with the electron-rich imidazolium ring [25].
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Table 1. Physical state, melting (Tm), cold crystallization (Tcc) and glass transition (Tg) temperatures of
the prepared ALN–OSILs.
Salt Physical State Tm/◦C Tcc/◦C * Tg/◦C
[TMGH][ALN] White solid 162.7 107.1 -
[TMGH]2[ALN] Colorless paste - - 97.5
[DBNH][ALN] White solid 130.3; 133.2 - -
[DBNH]2[ALN] Colorless paste - - 45.7
[C2OHMIM][ALN] Colorless paste - - 64.5
[C2OHMIM]2[ALN] White solid 153.0 (dec) - 46.3
[Ch][ALN] White solid 141.2 - 74.9
[Ch]2[ALN] Colorless paste - - 63.8
* Cold crystallization.
In comparison with sodium alendronate, which presents a melting temperature of 259.3 ◦C [26],
all solid compounds melt at lower temperatures, more specifically between 130.3 and 162.7 ◦C, for
[DBNH]- and [TMGH][ALN] OSILs, respectively. These melting temperatures are determined in the
third cycle of the experiment, which consists of heating from −90 ◦C to 150–190 ◦C (depending on the
compound) at 10 ◦C/min. The first two cycles typically consist of heating to 125 ◦C and isotherm for
15–20 min (for the complete removal of residual water) followed by cooling to −90 ◦C. From Cycle
3 onwards, consecutive cooling/heating cycles are performed at 10 or 20 ◦C/min. These cycles show
glass transition temperatures (Tg) for the majority of the ALN–OSILs, showing that they become
supercooled products, i.e., amorphous after the first melt. The exceptions to this behavior are [TMGH]
and [DNBH][ALN], to which no glass transition nor crystallization (Tc) temperatures were observed in
the experimental conditions. However, [TMGH][ALN] showed different behavior in comparison with
the remaining ALN–OSILs in the first cycle, in particular a cold crystallization (Tcc) peak at 107.1 ◦C
(Figure 3A).
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Figure 3. DSC thermograms of (A) [TMGH][ALN], (B) [TMGH]2[ALN], (C) [C2OHMIM][ALN] and
(D) [DBNH][ALN].
The DSC thermogram of the RTIL [TMGH]2[ALN] (Figure 3B) showed an endothermic signal at
ca. 150 ◦C of the third cycle that could be assigned to a melting process. However, it is pre eded by a
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glass transition at ca. 40 ◦C in the same cycle, meaning that the compound is in an amorphous state. So,
the referred endothermic signal is most likely due to evaporation, consistent with the irregular shape of
the curve caused by the formation of bubbles in the thick pasty compound. A similar observation can
also be observed in [C2OHMIM][ALN] (Figure 3C). From the set of eight compounds, [DBNH][ALN]
is the only one that possesses a polymorphic structure, given by the two melting temperatures at
130.3 and 133.2 ◦C recorded in the DSC thermogram (Figure 3D). The remaining RTILs, more precisely
[DBNH]2[ALN] and [Ch]2[ALN] show well-defined glass transitions confirming their amorphous
nature at room temperature (Figures S29 and S33, respectively).
4. Solubility Studies
As expected, all OSILs were more soluble in water and saline solution at 37 ◦C than alendronic
acid as well as its sodium salt. Figure 4 contains the data obtained from the solubility studies.
With the exception of the [DBNH]- and [C2OHMIM]-containing ILs, the dianionic ALN–OSILs
are equally or more soluble than the monoanionic siblings in the tested media. In further detail, it
is noteworthy that [TMGH]2[ALN], [DBNH][ALN] and [Ch]2[ALN] are completely soluble in both
water and saline solution in the tested conditions. Moreover, the [C2OHMIM]-, [C2OHMIM]2- and
[Ch]-based ALN–OSILs are also fully soluble in saline solution while the solubility in water was found
to be between 392 and 918 times higher in comparison with the parent neutral drug, and between
77 and 198 times when compared with Na[ALN]. In addition, [DBNH]2[ALN] presents full water
solubility and a 1682-fold increase in solubility in saline solution. Finally, [TMGH][ALN] shows the
lowest solubility in both media from the set of eight synthesized compounds.
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the starting materials of the synthesis, as well as the prepared ALN–OSILs upon incubation for 24 h 
are presented in Table 2. The cytotoxic effect of the ALN-OSILs on the cancer cell lines was also 
evaluated after 72h of exposure, and the data is presented in Table 3. A comparison with the standard 
anticancer drug paclitaxel is presented for both exposure times. 
i r Solub lity in water and saline solution at 37 ◦C of ALN, Na[ALN] and c rresponding
ALN–OSILs (detection limit is 5 g/mL, r pr sented by th upp r threshold).
5. Cytotoxicity on Human Cells
The c t toxicity f the prepared ALN–OSILs was determin d on hu an cells, by means of IC50
calculation. T e analysis was performed on human gingival fibroblasts (GF) and on different cancer
cell lines, namely T47D (breast), A549 (lung) and MG63 (osteosarcoma). The results obtained with the
starting materials of the synthe is, as well as the prepared ALN–OSILs upon incubation for 24 h are
presented in Table 2. The cytotoxic effect of the ALN-OSILs on the cancer cell lines was also evaluate
after 72h of exposure, and the data is resented in T ble 3. A comparison with the standard anticancer
drug paclitaxel is presented for both exposure times.
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Table 2. Cytotoxicity of the ALN–OSILs on GF cells and T47D, A549 and MG63 cell lines after 24 h.
IC50/mM
IL GF T47D A549 MG63
Paclitaxel 1.91 × 10−5 ±
0.34 × 10−5
6.46 × 10−6 ±
0.57 × 10−6
4.08 × 10−6 ±
0.60 × 10−6
8.19 × 10−6 ±
1.03 × 10−6
ALN 3.17 × 10−2 ±
0.12 × 10−2
4.09 × 10−3 ±
0.12 × 10−3 (*)
8.10 × 10−3 ±
0.88 × 10−3 (*)
5.55 × 10−4 ±
0.79 × 10−4 (*)
[TMGH]Cl 1.47 × 10−3 ±
0.40 × 10−3
1.94 × 10−4 ±
0.35 × 10−4
4.98 × 10−4 ±
0.55 × 10−4
2.46 × 10−4 ±
0.81 × 10−4
[DBNH]Cl 3.80 × 10−5 ±
0.53 × 10−5
2.78 × 10−4 ±
0.19 × 10−4
9.13 × 10−3 ±
1.03 × 10−3
9.79 × 10−8 ±
1.76 × 10−8
[Ch]Cl (a) (a) 5.99 × 10−3 ±
0.72 × 10−3
3.47 × 10−4 ±
0.52 × 10−4
[TMGH][ALN] 7.19 × 10−3 ±
0.97 × 10−3
8.23 × 10−3 ±
0.99 × 10−3
2.54 × 10−3 ±
0.32 × 10−3
9.23 × 10−3 ±
1.12 × 10−3
[TMGH]2[ALN] 1.11 × 10−3 ±
0.22 × 10−3
3.16 × 10−5 ±
0.25 × 10−5
5.14 × 10−4 ±
0.71 × 10−4
7.11 × 10−5 ±
0.85 × 10−5
[DBNH][ALN] 7.20 × 10−2 ±
0.55 × 10−2
(a) 6.14 ± 0.87 (a)
[DBNH]2[ALN] 6.01 × 10−5 ±
0.94 × 10−5
(a) 3.12 × 10−2 ±
0.45 × 10−2
1.02 ± 0.18
[C2OHMIM][ALN] 2.19 ± 0.32 5.92 × 10
−3 ±
0.69 × 10−3 (*)
2.10 × 10−6 ±
0.37 × 10−6 (*)
5.16 × 10−5 ±
0.67 × 10−5 (*)
[C2OHMIM]2[ALN]
4.07 × 10−4 ±
0.47 × 10−4
3.28 × 10−6 ±
0.40 × 10−6 (*) (a)
7.84 × 10−5 ±
0.98 × 10−5 (*)
[Ch][ALN] 1.87 × 10−1 ±
0.32 × 10−1 3.14 ± 0.43
6.66 × 10−2 ±
0.89 × 10−2 (*)
4.10 × 10−1 ±
0.62 × 10−1
[Ch]2[ALN]
4.92 × 10−3 ±
0.58 × 10−3
2.64 × 10−3 ±
0.38 × 10−3
5.41 × 10−3 ±
0.61 × 10−3
1.01 × 10−2 ±
0.14 × 10−2
(a) Not determined in the tested concentration range. (*) Significantly lower than GF; p < 0.05.
Table 3. Cytotoxicity of the ALN–OSILs on GF cells and T47D, A549 and MG63 cell lines after 72 h.
IC50/mM
IL GF T47D A549 MG63
Paclitaxel 5.66 × 10−5 ±
0.94 × 10−5
9.28 × 10−6 ±
1.02 × 10−6
7.83 × 10−6 ±
0.85 × 10−6
1.10 × 10−6 ±
1.25 × 10−6
ALN 9.26 × 10−2 ±
0.99 × 10−2
8.93 × 10−3 ±
1.53 × 10−3 (*)
1.46 × 10−2 ±
0.43 × 10−2 (*)
1.07 × 10−3 ±
0.26 × 10−3 (*)
[TMGH][ALN] 1.33 × 10−2 ±
0.51 × 10−2
1.84 × 10−2 ±
0.24 × 10−2
6.16 × 10−3 ±
0.94 × 10−3
1.64 × 10−2 ±
0.82 × 10−2
[TMGH]2[ALN]
1.68 × 10−3 ±
0.27 × 10−3
1.87 × 10−5 ±
0.43 × 10−5 (*)
9.84 × 10−4 ±
0.67 × 10−4
1.67 × 10−4 ±
0.25 × 10−4
[DBNH][ALN] 2.55 × 10−1 ±
0.34 × 10−1 (a) 0.99 ± 0.07 (a)
[DBNH]2[ALN]
1.65 × 10−4 ±
0.25 × 10−5 (a)
9.33 × 10−2 ±
1.00 × 10−2 1.14 ± 0.21
[C2OHMIM][ALN] 4.54 ± 0.66 1.14 × 10
−2 ±
0.25 × 10−2 (*)
5.65 × 10−6 ±
0.46 × 10−6 (*)
9.57 × 10−5 ±
0.91 × 10−5 (*)
[C2OHMIM]2[ALN]
6.21 × 10−4 ±
0.67 × 10−4
8.83 × 10−6 ±
0.94 × 10−6 (*) (a)
1.65 × 10−4 ±
0.26 × 10−4 (*)
[Ch][ALN] 7.33 × 10−1 ±
0.63 × 10−1 4.86 ± 0.55
7.84 × 10−2 ±
0.83 × 10−2 (*)
6.85 × 10−1 ±
0.85 × 10−1
[Ch]2[ALN]
8.57 × 10−3 ±
0.87 × 10−3
4.87 × 10−3 ±
0.65 × 10−3
8.94 × 10−3 ±
1.34 × 10−3
8.33 × 10−2 ±
0.93 × 10−2
(a) Not determined in the tested concentration range. (*) Significantly lower than GF, p < 0.05.
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Globally, it was observed that the IC50 values determined at 72 h of incubation were higher than
those obtained with a culture period of 24 h. The IC50 values obtained for paclitaxel in the tumor
cell lines were the lowest ones, which is in line with its well-known cytotoxic potential. However, it
showed no selectivity between healthy and cancer cells.
In the case of the ALN–OSILs, the obtained data clearly shows that the monoanionic OSILs elicited
lower cytotoxicity than the corresponding dianionic versions for all cell types. Regarding gingival
fibroblast cell cultures, the OSILs containing one unit of [DBNH], [C2OHMIM] and [Ch] appeared to
be less deleterious than alendronic acid. Comparatively, OSILs containing [TMGH]2, [C2OHMIM] and
[C2OHMIM]2 seemed to be more cytotoxic to breast cancer T47D cells. In the case of lung cancer A549
cell line, high cytotoxic activity was observed in cell cultures supplemented with the OSILs containing
[TMGH]2, [C2OHMIM] and [Ch]. Finally, osteosarcoma MG63 cell line seemed to be particularly
sensitive to the OSILs containing [TMGH]2, [C2OHMIM] and [C2OHMIM]2.
Breast and lung cancers are often associated with bone osteolytic metastases [27–29] and also
osteosarcoma, which are usually caused by disturbances in bone metabolism and increases in bone
turnover rates [6,30,31]. Thus, the development of OSILs with high cytotoxicity towards the tested
cancer cell types and containing an anti-resorbing molecule (alendronate) may represent a promising
strategy for the development of new pharmacological tools to be used in those pathological conditions.
Overall, [C2OHMIM][ALN] was found to be particularly active against lung cancer and
osteosarcoma cell lines while retaining very low toxicity towards healthy cells. These enhanced
biological properties, in addition to the absence of polymorphism in this monoanionic compound,
suggest that this room temperature ionic liquid could be a very promising alendronic acid formulation.
6. Experimental Section
6.1. General Procedure (A) for the Synthesis of ALN–OSILs with Organic Superbases as Cations
To a dispersion of alendronic acid (400 mg, 1.61 mmol) in MeOH/H2O (15 mL, 1:1) a methanolic
solution of 1 or 2 molar equivalents of organic superbase (15 mg/mL) was added dropwise at room
temperature under magnetic stirring. After reacting for 1 h, the solvent was evaporated and the desired
product was dried under vacuo for 24 h.
6.2. General Procedure (B) for the Preparation of ALN–OSILs with Ammonium and Methylmidazolium Cations
The halide salts of the selected ammonium and methylimidazolium cations were dissolved in
methanol and passed slowly through an anion-exchange column A-26(OH) (3 equivalents). The
freshly formed methanolic solutions of the corresponding hydroxide salts (1 or 2 equivalents) were
consequently added dropwise to alendronic acid (400 mg, 1.61 mmol) dispersed in H2O under magnetic
stirring at room temperature. After 1 h, the solvent of the clear solution was evaporated, and the
desired product was dried under vacuo for 24 h.
Toxicity studies are described as supporting information.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/12/3/293/s1,
Materials, experimental procedures, compound characterization data. Figures S1–S16: NMR spectra of ALN-OSILs;
Figures S17–S25: FTIR spectra of ALN and ALN-OSILs; Figures S26–S33: DSC thermograms of ALN-OSILs.
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Abbreviations
IL ionic liquid
ALN alendronic acid
ALN–OSILs alendronic acid-based ionic liquids and organic salts
RTILs Room Temperature Ionic Liquids
API–OSILs Active Pharmaceutical Ingredient Ionic Liquids and Organic Salts
TMG 1,1,3,3-tetramethylguanidine
DBN 1,5-diazabicyclo(4.3.0)non-5-ene
Ch choline
C2OHMIM 1-(2-hydroxyethyl)-3-methylimidazolium
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